SCHEMBL3166607

SCHEMBL3166607

CCc1ccc2cc(-c3ccc(F)cc3)ccc2c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
CYP2A6 P11509 1/20 0.53
LMNA P02545 1/20 0.46
PGR P06401 1/20 0.42
MAOB P27338 1/20 0.41
HRH3 Q9Y5N1 5/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GCGR P47871 1/20 0.39
MAPK14 Q16539 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
AGXT P21549 1/20 0.39
CYP17A1 P05093 1/20 0.38
SCN9A Q15858 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
PYCR1 P32322 1/20 0.38
BCL2 P10415 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3157962 1.00 CYP1A2 (0.53) CYP1A2CYP2A6LMNAPGRMAOB
SCHEMBL3158255 0.89 CYP1A2 (0.50) CYP1A2CYP2A6PGRHRH3AKR1C3
SCHEMBL3159151 0.87 CYP1A2 (0.52) CYP1A2CYP2A6LMNAPGRHRH3
SCHEMBL3255025 0.87 CYP1A2 (0.44) CYP1A2CYP2A6LMNAPGRMAOB
SCHEMBL3170570 0.87 CYP1A2 (0.44) CYP1A2CYP2A6LMNAAKR1C3AKR1C2
SCHEMBL3158271 0.86 TAAR1 (0.59) CYP1A2CYP2A6TAAR1AGXTCYP17A1
SCHEMBL3162460 0.85 HRH3 (0.47) LMNAPGRMAOBHRH3TAAR1
SCHEMBL3153827 0.85 CYP1A2 (0.50) CYP1A2CYP2A6HRH3AKR1C3AKR1C2
SCHEMBL3165761 0.85 HRH3 (0.47) LMNAPGRMAOBHRH3TAAR1
SCHEMBL3163338 0.84 TAAR1 (0.56) CYP1A2CYP2A6TAAR1CYP17A1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1452514-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2010-03-31 EP disclosed
EP-1273562-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2009-07-22 EP disclosed
CN-1291958-C Naphthacridine derivative and liquid crystal composite containing it DAINIPPON INK CHEMICAL IND CO (JP) 2006-12-27 CN disclosed
US-7145047-B2 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-12-05 US disclosed
EP-1452514-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-09-01 EP disclosed
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-07-24 US disclosed
EP-1273562-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-01-08 EP disclosed
US-6468607-B1 MISCIBILITY, LARGE BIREFRINGENCE INDEX, NO STRONGLY POLAR GROUP IN ITS MOLECULE AND THUS CAN ALSO BE USED FOR ACTIVE MATRIX DRIVING, WIDE TEMPERATURE RANGE AND REQUIRES A HIGH SPEED RESPONSE AND A LOW VOLTAGE DRIVING DAINIPPON INK AND CHEMICALS, INC. (JP) 2002-10-22 US disclosed
EP-0952135-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same NLK, NOTCH1, NOTCH4 CYP1A2 959/4885CYP2A6 3496/4885LMNA 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.